Personalized medicine for kids with tough cancers: genetic profiling may point to better treatments
NCT ID NCT02613962
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at whether analyzing the DNA and RNA of children's relapsed or treatment-resistant tumors can help doctors pick targeted therapies. Researchers profiled tumors from 791 children and adolescents using advanced genetic sequencing. The goal was to see how many patients could be matched to a specific targeted drug based on their tumor's unique molecular changes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors choose more effective, personalized treatments for children with cancer that has come back or not responded to standard therapy.
- What could go wrong
- This is an early-stage, observational study focused on feasibility, not a treatment trial. Many children may not have a targetable alteration, and even if they do, the matched therapy may not work or may have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY PEDIATRIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fondazione IRCCS Istituto
Milan, 20133, Italy
-
Gustave Roussy
Villejuif, Val de Marne, 94805, France
-
Hospital Universitari Vall D'Hebron
Barcelona, Catalonia, 08035, Spain
-
Our Lady's Children's Hospital
Dublin, Crumlin, 12, Ireland
-
Schneider Children's Medical Center
Petah Tikva, 49202, Israel